Re-Vana: Vision In The Future

Home
About Re-Vana
Products
- OcuLief
- EyeLief
The Team
Contact

Contact

Your Name (required)

Company Name

Your Profession/Title

Your Email (required)

Subject

Your Message

[recaptcha]

Contact

United Kingdom:
T: +44 (0) 28 9097 5814
E: info@re-vana.com

USA:
T: +1 (813) 323 1438
E: mor.revana@gmail.com

Mailing:
McClay Research Centre
97 Lisburn Road
Belfast, BT9 7BL
United Kingdom

Re-Vana Therapeutics Inc.
1027 South Dakota Ave
Tampa, FL 33606
USA

Nicox Enters Research Collaboration with Re-Vana Therapeutics

Re-Vana's technology offers us additional opportunities, alongside our recently announced collaboration with pSivida, to explore the potential for sustained-release delivery of our novel, next generation of stand-alone NO-donors. EyeLief(TM) technology has a number of unique properties that have shown promise in the delivery of drugs for the reduction of IOP. We look forward to working with Re-Vana on this innovative research endeavor.

Michael Bergamini, Executive Vice President and Chief Scientific Officer, Nicox

Re-Vana's design strategy

The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.

Contact Us

United Kingdom:
T: +44 (0) 28 9097 5814
E: info@re-vana.com

USA:
T: +1 (813) 323 1438
E: mor.revana@gmail.com

Mailing:
McClay Research Centre
97 Lisburn Road
Belfast, BT9 7BL
United Kingdom

Re-Vana Therapeutics Inc.
1027 South Dakota Ave
Tampa, FL 33606
USA